124034 Akt Inhibitor XV, Isozyme-Selective - Calbiochem

124034
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmarDisponibilidad a confirmar
En existencia 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service
      Ver precios y disponibilidad
      Click To Print This Page

      Descripción

      Replacement Information

      Tabla espec. clave

      Empirical Formula
      C₃₃H₂₉N₇O

      Precios y disponibilidad

      Número de referenciaDisponiblidad Embalaje Cant./Env. Precio Cantidad
      US1124034-2MG
      Comprobando disponibilidad...
      Disponibilidad a confirmarDisponibilidad a confirmar
      En existencia 
      Suspendido
      Cantidades limitadas disponibles
      Debe confirmarse disponibilidad
        El resto: se avisará
          El resto: se avisará
          Se avisará
          Póngase en contacto con el Servicio de Atención al Cliente
          Contact Customer Service

          Frasco de vidrio 2 mg
          Recuperando precio...
          No pudo obtenerse el precio
          La cantidad mínima tiene que ser múltiplo de
          Al finalizar el pedido Más información
          Ahorró ()
           
          Solicitar precio
          Description
          OverviewA cell-permeable naphthyridinone compound that acts as an allosteric Akt1/2-selective inhibitor (IC50 = 3.5, 42, and 1900 nM against Akt1, Akt2, and Akt3, respectively) in a PH domain-dependent, but not ATP-competitive, manner, with little activity against a panel of more than 160 other kinases, including the related AGC family kinases (inactive at 10 µM against GSK, PDK1, PKA, PKC, and SGK). Effectively inhibits the basal Akt phosphorylation in cancer cells with deregulated Akt pathway activation, including the HCT116 colorectal carcinoma and a panel of breast cancer cell lines (IC50 <500 nM), and suppresses Akt-dependent cell growth both in cultures in vitro (IC50 ≤1 µM) and in mice in vivo (50 to 100 mg/kg, SC). Although also referred to as AKTi-1/2, this is not the same compound as Akt Inhibitor XV (Cat. Nos. 124017 & 124018).
          Catalogue Number124034
          Brand Family Calbiochem®
          Synonyms5-Hydroxy-3-phenyl-2-(4-((4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperdin-1-yl)methyl)phenyl)-1,6-naphthyridine
          References
          ReferencesShe, Q.B., et al. 2010. Cancer Cell 18, 39.
          Bilodeau, M.T., et al. 2008. Bioorg. Med. Chem. Lett. 18, 3178.
          She, Q.B, et al. 2008. PLoS One 3, e3065.
          Product Information
          FormWhite powder
          Hill FormulaC₃₃H₂₉N₇O
          Chemical formulaC₃₃H₂₉N₇O
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Purity≥97% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Ficha datos de seguridad (MSDS)

          Título

          Ficha técnica de seguridad del material (MSDS) 

          Certificados de análisis

          CargoNúmero de lote
          124034

          Referencias bibliográficas

          Visión general referencias
          She, Q.B., et al. 2010. Cancer Cell 18, 39.
          Bilodeau, M.T., et al. 2008. Bioorg. Med. Chem. Lett. 18, 3178.
          She, Q.B, et al. 2008. PLoS One 3, e3065.
          Ficha técnica

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision02-November-2011 RFH
          Synonyms5-Hydroxy-3-phenyl-2-(4-((4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperdin-1-yl)methyl)phenyl)-1,6-naphthyridine
          DescriptionA cell-permeable naphthyridinone compound that acts as an allosteric Akt1/2-selective inhibitor (IC50 = 3.5, 42, and 1900 nM against Akt1, Akt2, and Akt3, respectively) in a PH domain-dependent, but not ATP-competitive, manner, with little activity against a panel of more than 160 other kinases, including the related AGC family kinases (inactive at 10 µM against GSK, PDK1, PKA, PKC, and SGK). Effectively inhibits the basal Akt phosphorylation in cancer cells with deregulated Akt pathway activation, including the HCT116 colorectal carcinoma and a panel of breast cancer cell lines (IC50 <500 nM), and suppresses Akt-dependent cell growth both in cultures in vitro (IC50 ≤1 µM) and in mice in vivo (50 to 100 mg/kg, SC). Although also referred to as AKTi-1/2, this is not the same compound as Akt Inhibitor XV (Cat. Nos. 124017 & 124018).
          FormWhite powder
          Chemical formulaC₃₃H₂₉N₇O
          Structure formulaStructure formula
          Purity≥97% by HPLC
          SolubilityDMSO (25 mg/ml)
          Storage +2°C to +8°C
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Standard Handling
          ReferencesShe, Q.B., et al. 2010. Cancer Cell 18, 39.
          Bilodeau, M.T., et al. 2008. Bioorg. Med. Chem. Lett. 18, 3178.
          She, Q.B, et al. 2008. PLoS One 3, e3065.